Approval Date: Oct 2021
A combination opioid agonist and NSAID indicated for the management of acute pain severe enough to require an opioid and for which alternative treatments are inadequate
Approval Date: Oct 2021
A biosimilar to Humira, this drug is now officially interchangeable with Humira for the treatment of moderate-to-severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, moderate-to-severe Crohn’s disease, moderate-to-severe ulcerative colitis, and moderate-to-severe chronic plaque psoriasis
Approval Date: Sep 2021
Indicated for the treatment of major depressive disorder, obsessive compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, and PTSD
Approval Date: Sep 2021
Indicated for the treatment of major depressive disorder (MDD)
Approval Date: Sep 2021
Indicated for the acute treatment of migraine with or without aura
Approval Date: Sep 2021
For the treatment of anxiety disorders in adults receiving stable, evenly divided, three times daily dosing with lorazepam tablets
Approval Date: Sep 2021
A once-daily medication indicated to help lower blood sugar with type 2 diabetes, in conjunction with diet and exercise
Approval Date: Sep 2021
Indicated for the acute treatment of migraine with or without aura
Approval Date: Sep 2021
Indicated for the preventive treatment of episodic migraine
Approval Date: Aug 2021
Adjunct treatment to diet and exercise to improve glycemic control in adults with type 2 diabetes